再鼎医药Zai Lab Limited（ZLAB）2020年20-F年度报告「NASDAQ」（英文版）（663页）.pdf

1、Table of Contents UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549 FORM 10-K (Mark One)Annual Report Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934For the fiscal year ended:December 31,2020Or Transition Report Pursuant to Section 13 or 15(d)of the Securities

2、 Exchange Act of 1934Commission file number:001-38205 ZAI LAB LIMITED(Exact Name of Registrant as Specified in its Charter)Cayman Islands 98-1144595(State or other jurisdiction ofincorporation or organization)(I.R.S.EmployerIdentification No.)4560 Jinke RoadBldg.1,Fourth FloorPudongShanghai,China 20

3、1210(Address of principal executive offices)(Zip Code)+86 21 6163 2588(Registrants Telephone Number,Including Area Code)Securities registered pursuant to Section 12(b)of the Act:Title of each class Trading Symbol(s)Name of each exchange on which registeredAmerican Depositary Shares,each representing

4、 1Ordinary Share,par value$0.00006 per share ZLAB The Nasdaq Global Market Ordinary Shares,par value$0.00006 per share*9688 The Stock Exchange of Hong Kong Limited *Included in connection with the registration of the American Depositary Shares with the Securities and Exchange Commission.The ordinary

5、 shares are not registered or listed fortrading in the United States but are listed for trading on The Stock Exchange of Hong Kong Limited.Securities registered pursuant to Section 12(g)of the Act:NoneIndicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of

6、the Securities Act.Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d)of the Exchange Act.Yes No Indicate by check mark whether the registrant:(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exc